[HTML][HTML] MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers
BL Jackson, A Grabowska, HL Ratan - BMC cancer, 2014 - Springer
BL Jackson, A Grabowska, HL Ratan
BMC cancer, 2014•SpringerBackground This non-systematic review article aims to summarise the progress made in
understanding the functional consequences of microRNA (miRNA) dysregulation in prostate
cancer development, and the identification of potential miRNA targets as serum biomarkers
for diagnosis or disease stratification. Results A number of miRNAs have been shown to
influence key cellular processes involved in prostate tumourigenesis, including apoptosis-
avoidance, cell proliferation and migration and the androgen signalling pathway. An …
understanding the functional consequences of microRNA (miRNA) dysregulation in prostate
cancer development, and the identification of potential miRNA targets as serum biomarkers
for diagnosis or disease stratification. Results A number of miRNAs have been shown to
influence key cellular processes involved in prostate tumourigenesis, including apoptosis-
avoidance, cell proliferation and migration and the androgen signalling pathway. An …
Background
This non-systematic review article aims to summarise the progress made in understanding the functional consequences of microRNA (miRNA) dysregulation in prostate cancer development, and the identification of potential miRNA targets as serum biomarkers for diagnosis or disease stratification.
Results
A number of miRNAs have been shown to influence key cellular processes involved in prostate tumourigenesis, including apoptosis-avoidance, cell proliferation and migration and the androgen signalling pathway. An overlapping group of miRNAs have shown differential expression in the serum of patients with prostate cancer of varying stages compared with unaffected individuals. The majority of studies thus far however, involve small numbers of patients and have shown variable and occasionally conflicting results
Conclusion
MiRNAs show promise as potential circulating biomarkers in prostate cancer, but larger prospective studies are required to validate particular targets and better define their clinical utility.
Springer